A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Aggressive Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Pralatrexate (Primary) ; Folic acid; Vitamin B12 analogues
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 19 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 09 May 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.